Abstract
AIM: A hospital-wide, unselected switch of ranibizumab to aflibercept in treatment of age-related macular degeneration (AMD) allowed us to compare the clinical effectiveness of these agents.
METHOD: In a single-center before-after, observational study design new AMD-patients started with aflibercept treatment in 2013-2014 were compared with a control group of AMD-patients on ranibizumab before the switch.
RESULTS: The mean difference in visual acuity (in logMAR units) after 1 year was comparable (+0.012 [aflibercept, n = 37] vs +0.17 [ranibizumab, n = 30], p = 0.154). However, the aflibercept-group did receive more intravitreal injections (5.8 vs 4.7 injections, p = 0.004) and were treated longer (265.7 vs 197.7 days; p = 0.011).
CONCLUSION: With no difference in clinical effectiveness, longer treatment intervals for aflibercept should be investigated.
| Original language | English |
|---|---|
| Pages (from-to) | 561-567 |
| Journal | Comparative Hepatology |
| Volume | 7 |
| Issue number | 6 |
| Early online date | 1 Jun 2018 |
| DOIs | |
| Publication status | Published - 2018 |
Keywords
- age-related macular degeneration
- anti-VEGF treatment
- comparative effectiveness research
- ranibizumab
- aflibercept